We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

244 hedge funds and large institutions have $3.12B invested in Axsome Therapeutics in 2023 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 70 increasing their positions, 88 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more call options, than puts

Call options by funds: $79.2M | Put options by funds: $41.4M

83% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 24

30% more funds holding in top 10

Funds holding in top 10: 10 → 13 (+3)

18% more capital invested

Capital invested by funds: $2.65B → $3.12B (+$473M)

8% more funds holding

Funds holding: 226 → 244 (+18)

2.6% more ownership

Funds ownership: 80.28% → 82.88% (+2.6%)

20% less repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 88

Holders
244
Holders Change
+18
Holders Change %
+7.96%
% of All Funds
3.56%
Holding in Top 10
13
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+30%
% of All Funds
0.19%
New
44
Increased
70
Reduced
88
Closed
24
Calls
$79.2M
Puts
$41.4M
Net Calls
+$37.9M
Net Calls Change
+$18.3M

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$62.9M
2
PA
Perceptive Advisors
New York
+$37.2M
3
Millennium Management
Millennium Management
New York
+$27.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$20.4M
5
BlackRock
BlackRock
New York
+$20.4M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$65.3M
2
NIP
Nicholas Investment Partners
California
-$20.9M
3
SCM
Soleus Capital Management
Connecticut
-$16.6M
4
Citadel Advisors
Citadel Advisors
Florida
-$13.8M
5
BI
BVF Inc
California
-$10M
Name Holding Trade Value Shares
Change 		Change in
Stake
FCM
51
Frontier Capital Management
Massachusetts
$7.55M -$4.4M -65,788 -41%
MB
52
MPM BioImpact
Massachusetts
$7.43M -$13.3K -199 -0.2%
Jane Street
53
Jane Street
New York
$7.39M -$2.19M -32,750 -26%
AGP
54
Artia Global Partners
Florida
$6.99M – – –
CS
55
Candriam SCA
Luxembourg
$6.77M +$2.34M +35,000 +70%
PCM
56
Peregrine Capital Management
Minnesota
$6.75M -$419K -6,274 -7%
LC
57
Lindbrook Capital
California
$6.69M -$15.6K -233 -0.3%
CC
58
Cannell & Co
New York
$6.59M -$1.43M -21,345 -20%
NIP
59
Nicholas Investment Partners
California
$6.58M -$20.9M -312,335 -79%
HSBC Holdings
60
HSBC Holdings
United Kingdom
$6.37M -$4.57M -68,375 -46%
Deutsche Bank
61
Deutsche Bank
Germany
$6.36M +$1.32M +19,806 +33%
RPAM
62
Rhenman & Partners Asset Management
Sweden
$6.3M +$2.61M +39,000 +97%
First Trust Advisors
63
First Trust Advisors
Illinois
$5.56M +$4.67M +69,909 New
PFM
64
Privium Fund Management
Netherlands
$5.55M – – –
MAP
65
Moody Aldrich Partners
Massachusetts
$5.32M -$452K -6,767 -9%
ACM
66
Atika Capital Management
New York
$5.31M -$287K -4,300 -6%
HS
67
HighVista Strategies
Massachusetts
$4.96M +$354K +5,299 +9%
HWAM
68
Hennion & Walsh Asset Management
New Jersey
$4.82M -$430K -6,430 -10%
Swiss National Bank
69
Swiss National Bank
Switzerland
$4.82M -$749K -11,200 -16%
Schroder Investment Management Group
70
Schroder Investment Management Group
United Kingdom
$4.64M +$3.9M +58,300 New
LIP
71
Lighthouse Investment Partners
Florida
$4.47M +$3.76M +56,202 New
WP
72
WMS Partners
Maryland
$4.04M -$2.01M -30,000 -37%
RhumbLine Advisers
73
RhumbLine Advisers
Massachusetts
$4.03M -$13.9K -208 -0.4%
AAA
74
Affinity Asset Advisors
New York
$3.98M +$3.34M +50,000 New
BWP
75
Baldwin Wealth Partners
Massachusetts
$3.9M +$66.9K +1,000 +2%
1 2
3
4 5

AXSM Hedge Fund Activity: Q4 2023 in Review

244 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2023, worth a combined $3.12B — up 18% from $2.65B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new AXSM positions and 24 closed out — a net gain of 20 holders — while 70 added to existing stakes and 88 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $62.9M. The largest seller was Fidelity Investments, cutting an estimated $65.3M.

  • 244 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2023, up from 226 in Q3 2023.
  • Funds reported $3.12B of Axsome Therapeutics stock for Q4 2023, up 18% quarter-over-quarter.
  • 44 funds opened new Axsome Therapeutics positions in Q4 2023 and 24 closed out, a net change of +20 holders.
  • The largest Axsome Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $62.9M added.
  • The largest Axsome Therapeutics seller in Q4 2023 was Fidelity Investments, an estimated $65.3M sold.

Based on aggregated 13F filings for Q4 2023.